Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
March 26, 2015 09:00 ET | Zogenix
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million
March 10, 2015 16:05 ET | Zogenix
Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline Conference Call and Webcast on Tuesday, March 10, at 4:30 p.m. ET Agreement...
Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results
March 10, 2015 16:05 ET | Zogenix
Clinical and Regulatory Update Received FDA approval for new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™ On track to begin...
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results
March 02, 2015 16:05 ET | Zogenix
SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
February 10, 2015 16:01 ET | Zogenix
SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix to Participate in Leerink Global Healthcare Conference
February 05, 2015 09:00 ET | Zogenix
SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
January 30, 2015 19:05 ET | Zogenix
SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Provides Business Update
January 12, 2015 07:30 ET | Zogenix
SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
December 03, 2014 16:30 ET | Zogenix
SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
December 01, 2014 08:30 ET | Zogenix
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...